Po Hien Ear
Overview
Explore the profile of Po Hien Ear including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
30
Citations
413
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Ear P, Marinoni I, Dayton T, Guenter R, Quelle D, Battistella A, et al.
Endocr Oncol
. 2025 Jan;
4(1):e240055.
PMID: 39822778
Current models for the study of neuroendocrine tumours (NETs) are severely limited. While (e.g. cell lines), (e.g. organoids) and (e.g. mice) models all exist, each has limitations. To address these...
2.
Shilyansky J, Chan C, Xiao S, Gribovskaja-Rupp I, Quelle D, Howe J, et al.
Surgery
. 2024 Dec;
179:108943.
PMID: 39665969
Objectives: Semaglutide is a glucagon-like peptide 1 (GLP-1) analog that binds to GLP-1 receptors (GLP-1R) on beta-cells and neuronal cells and is used for treating type 2 diabetes and obesity....
3.
Chang J, Suraju M, Tran C, Chan C, Ear P, Howe J, et al.
J Surg Res
. 2024 Jul;
302:53-63.
PMID: 39083906
Introduction: Studies conflict on whether sex influences survival in gastroenteropancreatic neuroendocrine tumors (GEP-NETs). GEP-NETs express receptors and genes responsive to female hormones. We hypothesized that women would have improved survival...
4.
Tow D, Chan C, Howe J, Ear P
Surgery
. 2023 Nov;
175(3):726-734.
PMID: 37914574
Background: Serotonin is emerging as a promising therapeutic target in tryptophan hydroxylase 1-positive tumors, but further mechanistic studies are needed to effectively target dysregulated serotonin metabolism. One challenge is a...
5.
Beyer G, Hueser S, Li R, Manika D, Lee M, Chan C, et al.
Surgery
. 2023 Nov;
175(3):605-612.
PMID: 37914572
Background: Gastroenteropancreatic neuroendocrine carcinomas are rare neoplasms with no effective treatments and poor prognosis. Few reliable preclinical models exist for the study of gastroenteropancreatic neuroendocrine carcinomas, limiting investigation of novel...
6.
Tow D, Tran C, Borbon L, Ridder M, Li G, Kaemmer C, et al.
bioRxiv
. 2023 Apr;
PMID: 37066322
Small bowel neuroendocrine tumors (SBNETs) originate from enterochromaffin cells in the intestine which synthesize and secrete serotonin. SBNETs express high levels of tryptophan hydroxylase 1 (Tph1), a key enzyme in...
7.
Sedlack A, Saleh-Anaraki K, Kumar S, Ear P, Lines K, Roper N, et al.
Cancers (Basel)
. 2022 Nov;
14(22).
PMID: 36428741
Neuroendocrine neoplasia (NENs) are a complex and heterogeneous group of cancers that can arise from neuroendocrine tissues throughout the body and differentiate them from other tumors. Their low incidence and...
8.
Vargas S, AghaAmiri S, Ghosh S, Luciano M, Borbon L, Ear P, et al.
Mol Pharm
. 2022 Sep;
19(11):4241-4253.
PMID: 36174110
Dye design can influence the ability of fluorescently labeled imaging agents to generate tumor contrast and has become an area of significant interest in the field of fluorescence-guided surgery (FGS)....
9.
Borbon L, Tran C, Sherman S, Ear P, Chandrasekharan C, Bellizzi A, et al.
Ann Surg Oncol
. 2022 Jul;
29(11):6936-6946.
PMID: 35802214
Background: Grade 3 (G3) gastroenteropancreatic (GEP) neuroendocrine neoplasms (NENs) are aggressive tumors with poor survival outcomes for which medical management is generally recommended. This study sought to evaluate outcomes of...
10.
Tran C, Borbon L, Mudd J, Abusada E, AghaAmiri S, Ghosh S, et al.
Cancers (Basel)
. 2022 Apr;
14(8).
PMID: 35454817
Gastroenteropancreatic neuroendocrine neoplasms (GEP NENs) are rare cancers consisting of neuroendocrine carcinomas (NECs) and neuroendocrine tumors (NETs), which have been increasing in incidence in recent years. Few cell lines and...